Drug Trial Radar · NCT02513095
Efficacy and Safety of Ryanodex® (EGL-4104) as Adjuvant Treatment in Subjects With Exertional Heat Stroke (EHS)
Last checked: Nov 19, 2026Latest source record: Jun 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
34
Actual
Start
Sep 2015
Primary completion
Sep 2015
Study completion Oct 2015
Sponsor
- Lead sponsor
- Eagle Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Quintiles, Inc.
- First posted
- Jul 31, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study EGL-4104-C-1502 is a phase 2, single-site, open-label, randomized, 2-arm parallel study of Ryanodex for the adjuvant treatment of exertional heat stroke (EHS) administered intravenously (IV), to current standard of care (SOC). SOC for the treatment of EHS is defined as effective body cooling, which should be implemented as quickly as available after diagnosis of exertional heat stroke.
Conditions
- Heat Stroke
Interventions
Dantrolene sodium for injectable suspensionDrug
Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Achieving Recovery of Level of Consciousness Defined as a Glasgow Coma Scale (GCS) GCS ≥ 13Time frame: 90 minutes post-randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Mecca, Saudi Arabia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.